Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 160

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 160
---
.

Competitive Advantages

We believe that we are positioned
to outperform competitors in the pharmaceutical industry for the following reasons:

| ● | We believe that the focus on a new product based                                           
 on resveratrol with higher bioavailability, JOTROL™, will enable us to utilize             
 the same product for several indications, subject to FDA’s approval. We believe that       
 this enables us to have several opportunities to obtain regulatory approval in case we are 
 able to show efficacy and safety acceptable to regulatory agencies for one or more of our  
 targeted indications.                                                                      |

| ● | JOTROL™ is an oral product based                                                          
 on a natural compound. Oral delivery of medications is a physician and patient preferred  
 treatment compared with injections and infusions and we expect that our product will have 
 an attractive and affordable price point for reimbursors and patients.                    |

| ● | We are building a close relationship with Key Opinion Leaders                                                                
 (“KOLs”) and patient organizations to facilitate a better understanding of patient needs and thereby design trials targeting 
 solutions to those needs as long as these targets are acceptable to the FDA.                                                 |

| ● | The natural product resveratrol is well studied with over 20,000                                                                              
 scientific publications to date. Published scientific papers, such as AY Berman et al, indicate that a highly bioavailable product generating 
 less GI side effects may have application in a number of indications.                                                                         |

| ● | Based upon available scientific literature, it                                                          
 appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin            
 family of proteins. SIRT1 deacetylates histones and nonhistone proteins including transcription         
 factors. The SIRT1-regulated pathway affects metabolism, stress resistance, cell survival,              
 cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms.        
 Resveratrol has been documented in scientific literature to activate SIRT1, NrF2, NLR3P inflammasomes   
 and have an epigenetic mechanism and therefore is predicted to benefit diseases affected                
 by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol           
 application is a major challenge for the pharmaceutical industry, due to its poor solubility            
 and bioavailability, as well as severe gastro-intestinal side effects when taken at effective           
 dose levels (over 2,000 mg daily). In this context, studies have proposed that